Product Information
CEVIMELINE HCL 30 MG CAPSULE is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.6871 per EA under NDC 00054033425. Its NADAC has been published 657 times since Nov 28, 2013.
Strength
30 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054033425
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
CEVIMELINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091591On Market Since
7/8/2013
Pharmacological Classes
Price Statistics
The NADAC for CEVIMELINE HCL 30 MG CAPSULE has been published 657 times since Nov 28, 2013, and over the history we have for it it has declined 68.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6871 per EA |
|---|---|
| All-time high | $2.2833 (Jan 15, 2014) |
| All-time low | $0.6268 (Nov 20, 2024) |
| 52-week high | $0.7172 |
| 52-week low | $0.6572 |
| Median price | $1.1463 |
| Average price | $1.2863 |
| Largest weekly change | +42.0% (Aug 17, 2022) |
| Weeks tracked | 657 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of CEVIMELINE HCL 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CEVIMELINE HCL 30 MG CAPSULE, manufactured by Hikma Pharmaceuticals USA Inc., is $0.6871 per EA (NDC 00054033425), effective Jun 24, 2026.
How has the price of CEVIMELINE HCL 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has declined 68.1%. It has been tracked across 657 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CEVIMELINE HCL 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has ranged from a low of $0.6268 (Nov 20, 2024) to a high of $2.2833 (Jan 15, 2014), with a median of $1.1463 per EA.
Are there cheaper alternatives to CEVIMELINE HCL 30 MG CAPSULE?
2 NADAC-published products share the same active ingredient, strength, and dosage form as CEVIMELINE HCL 30 MG CAPSULE, but none are currently priced below it.
Who manufactures CEVIMELINE HCL 30 MG CAPSULE?
CEVIMELINE HCL 30 MG CAPSULE (NDC 00054033425) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification